A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.

@article{Hanke2013ARP,
  title={A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.},
  author={Ch. Hanke and Rhoda S. Narins and Fredric Brandt and Joel E. Cohen and Lisa M. Donofrio and Jeanine Downie and Moritz M. Heinz and Laura M Harrington and David H McDaniel and Mark Steven Nestor and Joel Schlessinger and Andrea Schl{\"o}be and Amy Forman Taub and Robert A. Weiss},
  journal={Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]},
  year={2013},
  volume={39 6},
  pages={
          891-9
        }
}
BACKGROUND A prospective, randomized, double-blind, multicenter, Phase III trial of incobotulinumtoxinA using new Food and Drug Administration endpoints. OBJECTIVE To investigate the efficacy and safety of a single dose of incobotulinumtoxinA for the treatment of glabellar frown lines. MATERIALS AND METHODS Two hundred seventy-one subjects with moderate to severe glabellar frown lines at maximum frown-as assessed by an investigator according to the facial wrinkle scale (FWS)-were randomized… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 2 times. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Similar Papers

Loading similar papers…